The ECPM Advisory Board is composed of key stakeholders in medicines development representing academia, the pharmaceutical industry, regulatory authorities, the ECPM teaching faculty as well as representatives from the EUCOR medical schools and other partner universities.
The Advisory board meets annually toreview the outcome of the last yearand advises on new strategies for the future.
The aim of the advisory board is to ensure that ECPM training and research is always on trend with what is currently relevant in the industry, including, new developments, needs and trends. The advisory board members represent a critical sounding board and a think tank helping ECPM to evolve offerings to meet customer and market needs.
Members of the Advisory Board
Dr. Ruth Amstein, Zurich Heart House
Dr. Gerd Antes, Albert-Ludwigs-University
Dr. Rolf Heusser, National Institute for Cancer Epidemiology and Registration (NICER), Zurich
Dr. Marius Kränzlin, University of Basel
Dr. Martin Liechti, University of Basel
Prof. Martin Schumacher, Albert-Ludwigs-University, Freiburg i.Br.
PD Dr. Patricia Blank, Roche Diagnostics
Dr. Martine Clozel, Idorsia Pharmaceuticals Ltd.
Mr. Thomas Cueni, International Federation of Pharmaceutical Manufacturers
Dr. David R. Ebsworth, former Vifor Pharma AG
Dr. Djordje Filipovic, Novartis Pharma AG
Dr. med. Oliver Bleck , Roche Pharma (Schweiz) AG
Dr. Anthony Man, Novartis Pharma AG
Dr. Oliver Nayler, Actelion Pharmaceuticals Ltd.
Dr. Detlef Niese, former Novartis Pharma AG
Dr. Jörg Schläpfer, Swissmedic